Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ABL DiagnosticsFRA:9BK0 50 EV-to-FCF is 53.93 as of Jul. 19, 2026. GuruFocus rates FRA:9BK0 with a GF Score™ of 50/100 and a GF Value™ of €7.32 (Significantly Undervalued). The stock has 4 warning signs investors should review. Among 404 Healthcare Providers & Services companies, ABL Diagnostics ranks worse than 85.15% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, ABL Diagnostics's Enterprise Value is €38.56 Mil.
ABL Diagnostics's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was €0.72 Mil. Therefore, ABL Diagnostics's EV-to-FCF for today is 53.93.
The historical rank and industry rank for ABL Diagnostics's EV-to-FCF or its related term are showing as below:
FRA:9BK0'
s EV-to-FCF Range Over the Past 10 Years
Min: -57.19 Med: -0.93 Max: 87.73
Current: 53.93
During the past 13 years, the highest EV-to-FCF of ABL Diagnostics was 87.73. The lowest was -57.19. And the median was -0.93.
FRA:9BK0's EV-to-FCF is ranked worse than 85.15% of 404
companies
in the Healthcare Providers & Services industry
Industry Median: 18.215
vs FRA:9BK0: 53.93
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
ABL Diagnostics's PE Ratio (TTM) for today is calculated as:
ABL Diagnostics's share price for today is €2.76.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. ABL Diagnostics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was €0.061.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
ABL Diagnostics EV-to-FCF Related Terms
ABL Diagnostics EV-to-FCF Historical Data
* Premium members only.
The historical data trend for ABL Diagnostics's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Health Information Services subindustry, ABL Diagnostics's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ABL Diagnostics EV-to-FCF vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, ABL Diagnostics's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where ABL Diagnostics's EV-to-FCF falls into.
ABL Diagnostics's current Enterprise Value is €38.56 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. ABL Diagnostics's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was €0.72 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ABL Diagnostics (FRA:9BK0) has a EV-to-FCF of 53.93 as of Jul. 19, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on ABL Diagnostics and its competitors. According to the industry distribution chart, ABL Diagnostics ranks #344 out of 404 companies in the Healthcare Providers & Services industry, placing it in the top 85.1%.
Is ABL Diagnostics' EV-to-FCF too high?
ABL Diagnostics' current EV-to-FCF is 53.93. The Healthcare Providers & Services industry median EV-to-FCF is 18.22. ABL Diagnostics' value of 53.93 is 196.1% above this industry median. Based on the distribution chart, ABL Diagnostics ranks #344 out of 404 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, ABL Diagnostics has a GF Score™ of 50/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does ABL Diagnostics' EV-to-FCF compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, ABL Diagnostics ranks #344 out of 404 companies for EV-to-FCF. This places ABL Diagnostics in the lower half of its industry. The industry median EV-to-FCF is 18.22. ABL Diagnostics' value of 53.93 is 196.1% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Healthcare Providers & Services company?
The median EV-to-FCF among Healthcare Providers & Services companies is 18.22, based on 404 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. ABL Diagnostics's current EV-to-FCF of 53.93 is 196.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on ABL Diagnostics and its competitors. For the Healthcare Providers & Services industry, the median EV-to-FCF is 18.22 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ABL Diagnostics's current EV-to-FCF is 53.93. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ABL Diagnostics stock overvalued right now?
Based on GuruFocus' analysis, ABL Diagnostics (FRA:9BK0) is currently considered Significantly Undervalued. The stock's GF Value™ is €7.32, compared to a current price of €2.76 — trading 62.3% below its estimated fair value. The current EV-to-FCF is 53.93 and 196.1% above the Healthcare Providers & Services industry median of 18.22. ABL Diagnostics' overall GF Score™ is 50/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For ABL Diagnostics (FRA:9BK0), the current EV-to-FCF is 53.93 as of Jul. 19, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is ABL Diagnostics (FRA:9BK0) Overvalued in 2026?
Based on GuruFocus' analysis, ABL Diagnostics stock appears to be undervalued.
The current stock price of €2.76 is trading 62.3% below its estimated GF Value™ of €7.32.
GuruFocus considers ABL Diagnostics to be Significantly Undervalued.
Key valuation signals for FRA:9BK0:
EV-to-FCF: 53.93
GF Value™: €7.32 vs. price of €2.76 (62.3% below fair value)
Industry Position: 196.1% above the Healthcare Providers & Services median (#344 of 404)
No single metric tells the full story. See the FRA:9BK0 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
ABL Diagnostics is a diagnostic and medical software company. The group has focused on the development of software for collecting and processing medical databases, measuring the quality of care, diagnosing infectious diseases by genotyping, and providing decision support for doctors and nurses, virology and microbiology laboratories, and researchers dealing with patients suffering from chronic and complex diseases. It also develops, manufactures, and markets kits for clinical specimen collection.
50GF Score
Get the complete analysis for FRA:9BK0
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:9BK0 has been successfully added to your 
